BioSpace News Archive

Aspen Neuroscience, Inc. announced that Lisa Johnson-Pratt, MD has joined the company’s executive management team in a new role as Senior Vice President, Therapeutic Program Lead.

Oncolytics Biotech® Inc. announced the expansion of enrollment for the anal cancer cohort of the GOBLET study evaluating pelareorep in combination with atezolizumab in patients with second-line or later unresectable squamous cell carcinoma of the anal canal.

Kyowa Kirin Co., Ltd. announced that disease education and data from the Phase 2b study of rocatinlimab, an investigational product being studied in patients with moderate-to-severe atopic dermatitis, will be presented at the upcoming American Academy of Dermatology 2024 Annual Meeting in San Diego from March 8-12, 2024.

Veeva Systems announced that Boehringer Ingelheim has selected Veeva Vault Clinical and Veeva Vault RIM applications as its technology foundation for clinical and regulatory management in its animal health business unit.

VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences.

Antibe Therapeutics Inc. has filed its financial and operating results for the fiscal quarter ended December 31, 2023.

NextPoint Therapeutics announced today the closing of a $42.5M Extension to its Series B financing round resulting in a total of $122.5M raised in the Series B financing.

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its fourth quarter and full year 2023 financial results and provide an operational update for the Company on Tuesday, February 20, 2024, before the market opens.

Intellia Therapeutics, Inc. will present its fourth quarter and full-year 2023 financial results and operational highlights in a conference call on February 22, 2024, at 8 a.m. ET.

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (“Sonnet” or the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapeutic drugs for cancer, announced today its financial results for the three months ended December 31, 2023 and provided a business update.